We are live on ! Find out more
INM icon

InMed Pharmaceuticals
INM

9 hedge funds and large institutions have $665K invested in InMed Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,234% more capital invested

Capital invested by funds: $28.5K → $665K (+$637K)

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

29% more funds holding

Funds holding: 7 → 9 (+2)

14.46% more ownership

Funds ownership: 0.7% → 15.16% (+14%)

Holders
9
Holders Change
+2
Holders Change %
+28.57%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
1
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$530K
2
DS
DRW Securities
Illinois
+$86.5K
3
VF
Virtu Financial
New York
+$49.1K
4
Renaissance Technologies
Renaissance Technologies
New York
+$40.5K
5
TDC
Thompson Davis & Co
Virginia
+$24.7K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$25.2K
2
TRCT
Tower Research Capital (TRC)
New York
-$1.3K

INM Hedge Fund Activity: Q3 2025 in Review

9 of the 7,638 institutional investors tracked by Wall St. Rank reported a position in InMed Pharmaceuticals (INM) for Q3 2025, worth a combined $665K — up 2,234% from $28.5K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new INM positions and 3 closed out — a net gain of 2 holders — while 1 added to existing stakes and 0 trimmed.

The largest buyer was Sabby Management, opening a new position worth an estimated $530K. The largest seller was UBS Group, exiting entirely with an estimated $25.2K sold.

  • 9 institutional investors held InMed Pharmaceuticals (INM) as of Q3 2025, up from 7 in Q2 2025.
  • Funds reported $665K of InMed Pharmaceuticals stock for Q3 2025, up 2,234% quarter-over-quarter.
  • 5 funds opened new InMed Pharmaceuticals positions in Q3 2025 and 3 closed out, a net change of +2 holders.
  • The largest InMed Pharmaceuticals buyer in Q3 2025 was Sabby Management, an estimated $530K added.
  • The largest InMed Pharmaceuticals seller in Q3 2025 was UBS Group, an estimated $25.2K sold.

Based on aggregated 13F filings for Q3 2025.